RxDoctor Payments Data

Jerry Bell

Corneal and Contact Management · Parker, CONPI 1568452563

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 90.2% of the total across 85 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Johnson & Johnson Vision Care, Inc. at 46.8% of the total.

$2,088in general payments, 2019–2025

Across 85 payments — averaging $24.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Vision Care, Inc.$977
  • Coopervision Inc.$304
  • Alcon$204
  • Sun Pharmaceutical Industries Inc.$165
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$130
  • AbbVie$70
  • plus $238 from 8 others

What the payments were for

  • Consulting fees$20510%
  • Food & beverage$1,88390%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,088 in reported general payments places this provider in the 80th percentile of 33 corneal and contact management providers in Colorado.

See all corneal and contact management providers in Colorado

Medicare billing

Part B allowed, 2024
$44,816
Medicare patients
242
Services billed
502

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine30$33,681
LumiganBimatoprost28$17,568
Cyclosporine13$6,643
Alphagan PBrimonidine Tartrate19$5,558
RocklatanNetarsudil Mesylat/Latanoprost11$3,717
RhopressaNetarsudil Mesylate12$3,694
Travoprost15$1,354
Latanoprost190$1,031
Prednisolone Acetate13$720
Brimonidine Tartrate14$558
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha18$211
Timolol Maleate35$157

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P$70$56,80877 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 33 corneal and contact management providers in Colorado.

Other corneal and contact management in Parker

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →